Siga Ready For Next Phase, New Cash With Smallpox Drug Approval

 
• By Sue Sutter

Siga is entitled to a $41m “hold back” payment under its contract with the Biomedical Advanced Research and Development Authority and potentially a $50m payment related to the US FDA's extended shelf-life determination for stockpiled Tpoxx; company also picks up first priority review voucher awarded for a medical countermeasure, which it likely will monetize.

Variola virus, a virus from Orthopoxviridae family that causes smallpox, highly contagious disease eradicated by vaccination, 3D illustration
Tpoxx becomes the first drug approved to treat smallpox, which is caused by the variola virus.

More from New Products

More from Scrip